NXL103
NXL103 (formerly XRP 2868) is an experimental drug candidate under development by Novexel. It is an oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin-, macrolide- and quinolone-resistant strains.[1][2] It is a combination of linopristin and flopristin.[3]
Clinical trials[edit | edit source]
Positive results have been reported from a phase II trial comparing it with amoxicillin.[1] Another phase II trial will be run in 2010 comparing it with linezolid for treatment of acute bacterial skin and skin structure infections (ABSSSI).[4]
References[edit | edit source]
- ↑ 1.0 1.1 Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia, drugs.com
- ↑
- ↑ NXL103 at Novexel.com
- ↑ Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI), clinicaltrials.gov
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD
